CN103919853A - Preparation method for heart-protecting musk pill-containing mixed medicament for preventing and treating coronary heart disease and cardiac failure - Google Patents
Preparation method for heart-protecting musk pill-containing mixed medicament for preventing and treating coronary heart disease and cardiac failure Download PDFInfo
- Publication number
- CN103919853A CN103919853A CN201410151727.XA CN201410151727A CN103919853A CN 103919853 A CN103919853 A CN 103919853A CN 201410151727 A CN201410151727 A CN 201410151727A CN 103919853 A CN103919853 A CN 103919853A
- Authority
- CN
- China
- Prior art keywords
- heart
- musk
- pill
- heart disease
- coronary heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a preparation method for a heart-protecting musk pill-containing mixed medicament for preventing and treating coronary heart disease and cardiac failure. On the basis of conventional therapy, a heart-protecting musk pill is added to treat coronary heart disease and cardiac failure, clinical symptoms and cardiac function indexes of patients are further improved, no obvious side effect exists, and the mixed medicament is effective and safe in treating coronary heart disease and cardiac failure. The cardiac function is improved by at least two levels after treatment, and the symptoms and signs are completely or partially remitted.
Description
Technical field
The present invention relates to tcm field, especially a kind of prevention and the compound formulation that contain Heart pill of Musk mixing medicine for the treatment of coronary heart disease with heart failure.
Background technology
Heart failure refers to that various heart diseases cause a kind of syndrome of cardiac insufficiency, refer to that in most cases myocardial contraction decline makes cardiac output can not meet the needs of organism metabolism,, there is the performance of pulmonary circulation and (or) congestion of systemic circulation in organ, tissue blood hypoperfusion simultaneously.Heart failure is the end stage eventually of various heart diseases.
Along with quickening and the hypertension of aged tendency of population process, the rising of common cardiovascular diseases's sickness rate such as coronary heart disease, the prevalence of heart failure raises just gradually, according to statistics, the prevalence of crowd's central force exhaustion is about 1.5%-2.0%, and over-65s crowd can reach 6%-10%, due to China's large population base, at present, in 35-74 year adult, still approximately there are 4,000,000 heart failure patients, and along with hypertension, the increase of common cardiovascular diseases's sickness rate such as coronary heart disease, heart failure incidence is the trend of continuous rising, bring very big misery not only to patient and household thereof, and cause social heavy financial burden.Therefore, the treatment of heart failure has become society and the common important topic of paying close attention to of medical circle.
For a long time, with sorbide nitrate, spectinomycin hydrochloride, furosemide, the medicines such as captopril are treated heart failure in senile patients, although brought into play great role in the treatment of heart failure, but the treatment situation of heart failure not yet obtains thorough improvement, therapeutic effect is undesirable, be difficult to effectively reduce heart failure in senile patients case fatality rate and admission rate again, how improving life quality, 5 year life cycle of aged patients with congestive heart failure and reduce admission rate again, the medicine of developing new effective treatment heart failure has become an important subject of cardiovascular field.
Be 200510109554.6 to have announced a kind of pharmaceutical composition for the treatment of heart failure through retrieval request number, adopt Radix Ginseng Rubra, Radix Astragali Preparata, gun additioner, Herba Epimedii Preparata, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Fructus Aurantii Immaturus, Radix Ophiopogonis, Semen Lepidii (Semen Descurainiae), treatment heart failure in senile patients DeGrain, is difficult to effectively reduce heart failure in senile patients case fatality rate.
In view of the foregoing, now develop a kind of prevention and the compound formulation that contain Heart pill of Musk mixing medicine for the treatment of coronary heart disease with heart failure.
Summary of the invention
The object of the invention is in order to overcome deficiency of the prior art, a kind of prevention and the compound formulation that contain Heart pill of Musk mixing medicine for the treatment of coronary heart disease with heart failure are provided, on the basis of conventional therapy, add with Heart pill of Musk treatment coronary heart disease and heart failure, further improve patient clinical symptom and parameters of left ventricular function, and without obvious adverse reaction, be effective, the safe medication for the treatment of coronary heart disease and heart failure; After treatment, cardiac function improves more than 2 grades, and symptom, sign are alleviated wholly or in part.
The present invention to achieve these goals, adopt following technical scheme: a kind of prevention and the compound formulation that contain Heart pill of Musk mixing medicine for the treatment of coronary heart disease with heart failure: the assembly percentage by weight of each component is, Heart pill of Musk 25-85%, sorbide nitrate 5-10%, spectinomycin hydrochloride 6.25-25%, furosemide 10-40%, spironolactone 10-40%, captopril 12.5-50%, aspirin 15-70%, atorvastatin 10-20%, above each component by weight ratio sum is 100%.
The assembly percentage by weight of each component is, Heart pill of Musk 26-75%, sorbide nitrate 5-9%, spectinomycin hydrochloride 6.25-15%, furosemide 10-30%, spironolactone 10-30%, captopril 14.5-50%, aspirin 15-65%, atorvastatin 10-20%, above each component by weight ratio sum is 100%.
The assembly percentage by weight of each component is, Heart pill of Musk 28-85%, sorbide nitrate 5-9%, spectinomycin hydrochloride 6.25-25%, furosemide 14-40%, spironolactone 10-34%, captopril 12.5-30%, aspirin 15-68%, atorvastatin 10-15%, above each component by weight ratio sum is 100%.
In order to show curative effect of the present invention, now extract each 6 people for the treatment of group and matched group, the there was no significant difference (P > 0.05) such as two groups of Genders, age, degree of heart failure, basic cause of disease has comparability.Matched group gives conventional therapy medicine, and treatment group adds on this basis with Heart pill of Musk, draws following table:
Treatment group case:
| Name | Sex | Age | Disease | Angina pectoris rank | Cardiac function classification | Curative effect |
| Zhu XX | Man | 80 | Coronary heart disease | CCSIII level | III level | Effective |
| Bag X | Man | 80 | Coronary heart disease | CCSIII level | III level | Effective |
| Military XX | Female | 77 | Coronary heart disease | CCSII level | III level | Effective |
| Clock X | Man | 86 | Coronary heart disease | CCSIII level | IV level | Effective |
| Shen XX | Man | 82 | Coronary heart disease | CCSIII level | IV level | Effective |
| Thank to XX | Man | 76 | Coronary heart disease | CCSII level | II level | Effectively |
Matched group case:
| Name | Sex | Age | Disease | Angina pectoris rank | Cardiac function classification | Curative effect |
| The XX of Soviet Union | Female | 82 | Hypertensive cardiopathy | ? | II level | Effectively |
| Fourth XX | Man | 78 | Coronary heart disease | CCSII level | III level | Effective |
| High XX | Man | 83 | Coronary heart disease | CCSII level | IV level | Effectively |
| King XX | Man | 82 | Coronary heart disease | CCSIII level | III level | Effective |
| Close XX | Man | 81 | Coronary heart disease | CCSIII level | IV level | Effectively |
| Old XX | Man | 70 | Coronary heart disease | CCSII level | IV level | Effectively |
Treatment group and matched group comparing result:
| Group | N | Effective | Effectively | Invalid | Total effective rate |
| Treatment group | 6 | 5(83.3) | 1(16.7) | 0 | 6(100) |
| Matched group | 6 | 2(33.3) | 4(66.7) | 0 | 6(100) |
The invention has the beneficial effects as follows: Heart pill of Musk is taking famous prescription Styrax Pilulae of Song dynasty as basis; develop the Chinese patent medicine for the treatment of heart failure in conjunction with modern medicine; Heart pill of Musk is made up of seven Chinese medicines; main component is Moschus, Radix Ginseng extract, Styrax, artificial Calculus Bovis, Venenum Bufonis, Cortex Cinnamomi, Borneolum Syntheticum; can not only the logical temperature of fragrance, alleviate uncomfortable in chest, chest pain, again can righting QI invigorating, heart tonifying consolidates.Zoopery in recent years and human research's demonstration, Heart pill of Musk has coronary artery dilator, reduces heart infarction area, and the reaction of prevention left ventricular remodeling inflammation-inhibiting, stablizes atheromatous plaque, promotes myocardial vascular new life's effect.
Pharmacological mechanism of the present invention is: Moschus has the blood vessel of expansion, hypotensive activity, can reduce cardiac afterload; Radix Ginseng has heart tonifying, blood fat reducing, removing free radical, inhibition vascular smooth muscle hypertrophy, reverses the effect of Myocardial Remodeling; Styrax, Borneolum Syntheticum have the effect of decreased heart rate, Reduce of Coronary Spasm: Venenum Bufonis also has the function of heart tonifying, antiinflammatory.The diabetes rat that staff gives streptozotocin induction gavages Heart pill of Musk discovery after 8 weeks, rat heart muscle interstitial fibrosis obviously alleviates, left chamber diastasis pressure declines, left chamber systolic and diastolic function improves, prove that Heart pill of Musk can reduce the level of plasma renin activity and the angiotensin of rats with heart failure after myocardial infarction, improve EF, heavy dose of group effect is more remarkable.Modern pharmacology studies confirm that, Moschus, Venenum Bufonis, Calculus Bovis, Styrax, Cortex Cinnamomi have respectively antiplatelet, anticoagulant, antiinflammatory action, and each medicine reasonable compatibility, more obviously increases drug effect.
The present invention adds with Heart pill of Musk treatment coronary heart disease and heart failure on the basis of conventional therapy, further improves patient clinical symptom and parameters of left ventricular function, and without obvious adverse reaction, is effective, the safe medication for the treatment of coronary heart disease and heart failure; After treatment, cardiac function improves more than 2 grades, and symptom, sign are alleviated wholly or in part.
Detailed description of the invention
Below in conjunction with embodiment and detailed description of the invention, the present invention is described in further detail:
Embodiment 1
The assembly percentage by weight of each component is, Heart pill of Musk 25-85%, sorbide nitrate 5-10%, spectinomycin hydrochloride 6.25-25%, furosemide 10-40%, spironolactone 10-40%, captopril 12.5-50%, aspirin 15-70%, atorvastatin 10-20%, above each component by weight ratio sum is 100%.
Embodiment 2
The assembly percentage by weight of each component is, Heart pill of Musk 26-75%, sorbide nitrate 5-9%, spectinomycin hydrochloride 6.25-15%, furosemide 10-30%, spironolactone 10-30%, captopril 14.5-50%, aspirin 15-65%, atorvastatin 10-20%, above each component by weight ratio sum is 100%.
Embodiment 3
The assembly percentage by weight of each component is, Heart pill of Musk 28-85%, sorbide nitrate 5-9%, spectinomycin hydrochloride 6.25-25%, furosemide 14-40%, spironolactone 10-34%, captopril 12.5-30%, aspirin 15-68%, atorvastatin 10-15%, above each component by weight ratio sum is 100%.
Claims (3)
1. a prevention and the compound formulation that contain Heart pill of Musk mixing medicine for the treatment of coronary heart disease with heart failure: the assembly percentage by weight of each component is, Heart pill of Musk 25-85%, sorbide nitrate 5-10%, spectinomycin hydrochloride 6.25-25%, furosemide 10-40%, spironolactone 10-40%, captopril 12.5-50%, aspirin 15-70%, atorvastatin 10-20%, above each component by weight ratio sum is 100%.
2. a kind of prevention according to claim 1 and the compound formulation that contain Heart pill of Musk mixing medicine for the treatment of coronary heart disease with heart failure: the assembly percentage by weight of each component is, Heart pill of Musk 26-75%, sorbide nitrate 5-9%, spectinomycin hydrochloride 6.25-15%, furosemide 10-30%, spironolactone 10-30%, captopril 14.5-50%, aspirin 15-65%, atorvastatin 10-20%, above each component by weight ratio sum is 100%.
3. a kind of prevention according to claim 1 and the compound formulation that contain Heart pill of Musk mixing medicine for the treatment of coronary heart disease with heart failure: the assembly percentage by weight of each component is, Heart pill of Musk 28-85%, sorbide nitrate 5-9%, spectinomycin hydrochloride 6.25-25%, furosemide 14-40%, spironolactone 10-34%, captopril 12.5-30%, aspirin 15-68%, atorvastatin 10-15%, above each component by weight ratio sum is 100%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410151727.XA CN103919853A (en) | 2014-04-04 | 2014-04-04 | Preparation method for heart-protecting musk pill-containing mixed medicament for preventing and treating coronary heart disease and cardiac failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410151727.XA CN103919853A (en) | 2014-04-04 | 2014-04-04 | Preparation method for heart-protecting musk pill-containing mixed medicament for preventing and treating coronary heart disease and cardiac failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103919853A true CN103919853A (en) | 2014-07-16 |
Family
ID=51138395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410151727.XA Pending CN103919853A (en) | 2014-04-04 | 2014-04-04 | Preparation method for heart-protecting musk pill-containing mixed medicament for preventing and treating coronary heart disease and cardiac failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103919853A (en) |
-
2014
- 2014-04-04 CN CN201410151727.XA patent/CN103919853A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102228525A (en) | Traditional Chinese medicine for treating cardio-cerebral vascular stagnation | |
| CN100333750C (en) | Chinese medicinal preparation for treating qi obstruction in chest and heart palpitation and its preparation process | |
| CN101422562A (en) | Medicine for treating premature beat and atrial fibrillation | |
| CN104069446A (en) | Traditional Chinese medicine composition for treating angina pectoris | |
| CN103505612A (en) | Traditional Chinese medicine composition containing total flavonoids of sea-buckthorn and preparation method of composition | |
| CN103919852A (en) | Blending method of heart-protecting pill mixed powder containing musk for preventing and treating chronic cardiac insufficiency and heart failure | |
| CN104906274A (en) | Traditional Chinese medicine for treating coronary heart disease | |
| CN103908490A (en) | Pure plant traditional Chinese medicinal preparation for treating myocardial infarction and cardiovascular diseases and preparation method thereof | |
| CN106138831A (en) | A kind of Chinese medicine composition treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN103919853A (en) | Preparation method for heart-protecting musk pill-containing mixed medicament for preventing and treating coronary heart disease and cardiac failure | |
| CN101991665B (en) | Composition for treating myocardial diseases, femoral head necrosis and tumor and preparation process thereof | |
| CN103893262A (en) | Forming method of mixed drug containing musk heart-protecting pill for preventing and treating chronic heart failure | |
| CN105213519A (en) | A kind of medicine and preparation method thereof for the treatment of prolapse of lumbar intervertebral disc, hyperosteogeny | |
| CN103893264A (en) | Method for dispensing mixed medicament containing heart-protecting musk pill for preventing and treating carotid atherosclerotic plaque and heart failure | |
| CN103893263A (en) | Preparation method of mixed medicine containing heart-protecting musk pill for preventing and treating angina pectoris and chronic cardiac insufficiency | |
| CN103520498A (en) | Chinese medicinal composition for treating cerebral arteriosclerosis neurasthenia syndrome | |
| CN103055159B (en) | Medicine for treating hypertension | |
| CN108126101A (en) | It is a kind of to be used to treat pharmaceutical preparation of diabetic cardiomyopathy and preparation method thereof | |
| CN102526343B (en) | Traditional Chinese medicine composition for tonifying qi, activating blood and dredging collaterals | |
| CN100569252C (en) | The medicine and the preparation method of treatment essential hypertension | |
| CN104524313A (en) | Traditional Chinese medicine preparation for treating sick sinus syndrome | |
| CN104096112A (en) | Traditional Chinese medicine composition for treating angina pectoris | |
| CN104645020A (en) | Traditional Chinese medicine composition for treating coronary heart disease and angina and application of traditional Chinese medicine composition | |
| CN1116884C (en) | Compound Cijin capsule | |
| CN105012855A (en) | Medicine composition for treating stroke, as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140716 |
|
| RJ01 | Rejection of invention patent application after publication |